Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fennec Pharmaceuticals (FRX) has provided an update.
Adrian Haigh has stepped down as Chief Operating Officer of Fennec Pharmaceuticals Inc., after transitioning to the role in August 2023 and serving as an independent director for nine years. In line with his departure, Haigh and the company have agreed to a Confidential Separation Agreement, which includes the acceleration of options vesting for Haigh to purchase company shares at a set price before they expire in mid-2027.
See more data about FRX stock on TipRanks’ Stock Analysis page.